Business Context and Reporting Period
This Form 8-K filing by Relmada Therapeutics, Inc. covers events occurring on December 22, 2015, with the report dated December 23, 2015. The filing addresses a significant legal development involving a proxy contest and allegations of false and misleading communications by Laidlaw & Company (UK) Ltd. and its principals.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal proceedings and corporate governance disputes rather than financial performance.
Material Changes and Legal Developments
On December 22, 2015, the U.S. District Court for the District of Nevada entered a preliminary injunction against Laidlaw & Company (UK) Ltd. and its principals, Matthew Eitner and James Ahern. The Court ordered the Defendants to:
- Immediately retract or correct false and misleading proxy materials.
- Disclose that they missed the advance notice deadline for nominating directors at the 2015 annual meeting.
- Disclose that only two seats are up for election on the Board.
- Disclose that the Board has sole authority to set the Board size.
- Disclose that corporate actions labeled as "entrenchment" by the Defendants were authorized under Relmada's articles of incorporation, bylaws, and Nevada law.
This Order extends a temporary restraining order issued on December 10, 2015, following a lawsuit filed by Relmada on December 9, 2015, alleging violations of Rule 14a-9 of the Securities Exchange Act of 1934.
Outlook, Risks, and Contingencies
The preliminary injunction remains in place pending a full trial on the merits. The primary risk identified is the ongoing legal dispute regarding the validity of proxy materials and the conduct of the proxy contest. Management asserts that the Defendants' materials contain material misrepresentations and omissions in violation of federal securities laws.
Investor Verification Checklist
- Verify the specific terms of the preliminary injunction attached as Exhibit 99.2.
- Review the press release issued on December 23, 2015 (Exhibit 99.1) for management's full statement.
- Confirm the status of the 2015 annual meeting and the specific director seats up for election.
- Monitor for updates regarding the scheduled full trial on the merits.